XML 83 R73.htm IDEA: XBRL DOCUMENT v3.22.2.2
SHAREHOLDERS' EQUITY (Details) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended
Feb. 12, 2021
Feb. 09, 2021
May 20, 2020
Sep. 30, 2022
Sep. 30, 2021
Dec. 17, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock offering, shares sold (in shares) 8,750,000 5,650,000        
Stock offering, purchase price (in dollars per share) $ 3.92 $ 2.48        
Stock offering, gross proceeds $ 34.3 $ 14.0        
Stock offering, net proceeds $ 32.2 $ 13.1        
Warrants exercised (in shares)       0 392,095  
Common shares issued (in shares)       0 387,802  
Warrants outstanding       $ 0.0    
Zyla Life Sciences | Iroko | Warrant Agreements            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Exercise aggregate ownership percentage maximum threshold     49.00%      
Exercise aggregate ownership percentage term     18 months      
Zyla Life Sciences | Money market funds | Zyla Life Sciences            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Purchase price, number of shares outstanding, per share (in dollars per share)     $ 0.0016      
At The Market Program            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Aggregate offering price           $ 25.0
Stock offering, shares sold (in shares)       2,463,637    
Stock offering, purchase price (in dollars per share)       $ 3.02    
Stock offering, gross proceeds       $ 7.4    
Stock offering, net proceeds       $ 7.0